Business Standard

MSCI sets aside Piramal Pharma's exclusion from global standard index

The company was listed separately on October 19, following its demerger from Piramal Enterprises

Premium

BS Reporter
Global index provider Morgan Stanley Capital International (MSCI) has set aside the excision of Piramal Pharma Solutions (Piramal Pharma) from its Global Standard Index after the stock hit the lower trading limit.

Shares of Piramal Pharma dropped 5 per cent to close at Rs 163.3 on the BSE. The stock has hit a lower trading limit in three of the five trading sessions since its listing.

The removal from the MSCI index is likely to result in selling by passive trackers to the tune of $50 million, according to Nuvama Alternative & Quant Research.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 27 2022 | 6:51 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com